Grade ≥3 treatment-related adverse events occurred in 51.5% (n=17) of patients with the most common (≥10%) being increase in aspartate aminotransferase (21.2%), lymphopenia (18.2%), increase in alanine aminotransferase (15.2%), CRS (12.1%), and neutropenia, (12.1%). This evidence concerns the gene GPT and congenital rubella syndrome.